BACKGROUND: Multidrug resistance has become a quandary in the treatment of bacterial infections. The effect of resistance mutations and the fitness cost on the pathogenicity of Pseudomonas aeruginosa is not well established. The objective of this study was to examine the impact of multidrug resistance on the fitness and virulence of P. aeruginosa. METHODS: Fourteen P. aeruginosa strains with various resistance mechanisms were used. In vitro growth of these isolates was investigated in full-strength and 0.25-strength Mueller-Hinton broth (MHB). Exponential growth rates were estimated from serial bacterial burden over 24 h. In vitro growth of two multidrug-resistant strains (PAO1ΔmexRΔoprD and PA9019) was studied when each was grown in co-culture with wild-type strain PAO1. In vivo growth was compared between PAO1 and PAO1ΔmexRΔopD using a murine pneumonia model; virulence over 10 days was studied in six isolates. RESULTS: Significant reduction in growth rate was observed in selected mutants (P < 0.01). PAO1 out-competed PAO1ΔmexRΔoprD and PA9019 in vitro, and in vivo growth of PAO1 was faster than PAO1ΔmexRΔoprD. Compared with PAO1, PAO1ΔmexR and PAO1ΔoprD showed a slight reduction in mortality rate; significantly lower mortality was seen in PAO1ΔmexRΔoprD (P < 0.01). However, virulence of PA9019 was not significantly different from that of PAO1. CONCLUSIONS: Specific resistance mutations were associated with fitness cost in P. aeruginosa, and accumulation of such mutations was associated with a reduction in virulence. However, it was difficult to predict the impact in clinical isolates. Knowledge of multidrug resistance mechanisms and compensatory mutations would likely be helpful.
BACKGROUND: Multidrug resistance has become a quandary in the treatment of bacterial infections. The effect of resistance mutations and the fitness cost on the pathogenicity of Pseudomonas aeruginosa is not well established. The objective of this study was to examine the impact of multidrug resistance on the fitness and virulence of P. aeruginosa. METHODS: Fourteen P. aeruginosa strains with various resistance mechanisms were used. In vitro growth of these isolates was investigated in full-strength and 0.25-strength Mueller-Hinton broth (MHB). Exponential growth rates were estimated from serial bacterial burden over 24 h. In vitro growth of two multidrug-resistant strains (PAO1ΔmexRΔoprD and PA9019) was studied when each was grown in co-culture with wild-type strain PAO1. In vivo growth was compared between PAO1 and PAO1ΔmexRΔopD using a murinepneumonia model; virulence over 10 days was studied in six isolates. RESULTS: Significant reduction in growth rate was observed in selected mutants (P < 0.01). PAO1 out-competed PAO1ΔmexRΔoprD and PA9019 in vitro, and in vivo growth of PAO1 was faster than PAO1ΔmexRΔoprD. Compared with PAO1, PAO1ΔmexR and PAO1ΔoprD showed a slight reduction in mortality rate; significantly lower mortality was seen in PAO1ΔmexRΔoprD (P < 0.01). However, virulence of PA9019 was not significantly different from that of PAO1. CONCLUSIONS: Specific resistance mutations were associated with fitness cost in P. aeruginosa, and accumulation of such mutations was associated with a reduction in virulence. However, it was difficult to predict the impact in clinical isolates. Knowledge of multidrug resistance mechanisms and compensatory mutations would likely be helpful.
Authors: Elena Martinez; Carolina Marquez; Ana Ingold; John Merlino; Steven P Djordjevic; H W Stokes; Piklu Roy Chowdhury Journal: Antimicrob Agents Chemother Date: 2012-01-23 Impact factor: 5.191
Authors: Xavier Mulet; Gabriel Cabot; Alain A Ocampo-Sosa; M Angeles Domínguez; Laura Zamorano; Carlos Juan; Fe Tubau; Cristina Rodríguez; Bartolomé Moyà; Carmen Peña; Luis Martínez-Martínez; Antonio Oliver Journal: Antimicrob Agents Chemother Date: 2013-08-26 Impact factor: 5.191
Authors: Yiying Cai; Tze-Peng Lim; Jocelyn Teo; Suranthran Sasikala; Winnie Lee; Yanjun Hong; Eric Chun Yong Chan; Thean Yen Tan; Thuan-Tong Tan; Tse Hsien Koh; Li Yang Hsu; Andrea L Kwa Journal: Antimicrob Agents Chemother Date: 2016-08-22 Impact factor: 5.191
Authors: Irina Sánchez-Diener; Laura Zamorano; Carla López-Causapé; Gabriel Cabot; Xavier Mulet; Carmen Peña; Rosa Del Campo; Rafael Cantón; Antonio Doménech-Sánchez; Luis Martínez-Martínez; Susana C Arcos; Alfonso Navas; Antonio Oliver Journal: Antimicrob Agents Chemother Date: 2017-11-22 Impact factor: 5.191
Authors: Silvia Gómez-Zorrilla; Mariana Camoez; Fe Tubau; Rosario Cañizares; Elisabet Periche; M Angeles Dominguez; Javier Ariza; Carmen Peña Journal: Antimicrob Agents Chemother Date: 2015-06-15 Impact factor: 5.191
Authors: Carmen Peña; Cristina Suarez; Mónica Gozalo; Javier Murillas; Benito Almirante; Virginia Pomar; Manuela Aguilar; Ana Granados; Esther Calbo; Jesús Rodríguez-Baño; Fernando Rodríguez; Fe Tubau; Luis Martínez-Martínez; Antonio Oliver Journal: Antimicrob Agents Chemother Date: 2011-12-12 Impact factor: 5.191